Brief: Ultimovacs Announces Positive Three-Year Results In Cohort 1 Of UV1-103 Study In Metastatic Malignant Melanoma
05/10/2022 18:29
Oct 5 (Reuters) - Ultimovacs ASA ULTI.OL :
* REG-ULTIMOVACS ANNOUNCES POSITIVE THREE-YEAR RESULTS OF
71%
OVERALL SURVIVAL RATE IN COHORT 1 OF UV1-103 STUDY IN METASTATIC
MALIGNANT MELANOMA
* ULTIMOVACS ASA- UV1 AND PEMBROLIZUMAB COMBINATION
CONTINUES TO
DEMONSTRATE STRONG SIGNALS OF CLINICAL EFFICACY, INCLUDING
PROLONGED PATIENT SURVIVAL
Source text for Eikon: ID:nGNE3bD96w
Further company coverage: ULTI.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant